Compare VNRX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | LSTA |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 28.9M |
| IPO Year | 2012 | 2000 |
| Metric | VNRX | LSTA |
|---|---|---|
| Price | $0.72 | $0.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $1.67 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 239.0K | 104.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | $1,727,384.00 | ★ $35,283,868.00 |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 40.04 | ★ 56.90 |
| 52 Week Low | $0.13 | $1.01 |
| 52 Week High | $3.26 | $5.07 |
| Indicator | VNRX | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 23.93 | 14.19 |
| Support Level | $0.19 | N/A |
| Resistance Level | $1.55 | $2.19 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 4.84 | 0.70 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.